

Khang-Li Looi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/856400/publications.pdf>

Version: 2024-02-01

19
papers

210
citations

1163117

8
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

363
citing authors

#	ARTICLE	IF	CITATIONS
1	Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1669-1678.	2.8	56
2	Cardiac resynchronisation therapy: pacemaker versus internal cardioverter-defibrillator in patients with impaired left ventricular function. <i>Heart</i> , 2014, 100, 794-799.	2.9	27
3	Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. <i>Europace</i> , 2016, 18, 1187-1193.	1.7	25
4	Sex-specific outcomes with addition of defibrillation to resynchronisation therapy in patients with heart failure. <i>Heart</i> , 2017, 103, 753-760.	2.9	21
5	Long-term outcomes (>2 years) of atrial fibrillation ablation using a multi-electrode ablation catheter in patients with paroxysmal atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 36, 61-69.	1.3	16
6	Conscious sedation and analgesia use in cardiac device implantation. <i>International Journal of Cardiology</i> , 2013, 168, 561-563.	1.7	12
7	Ventricular arrhythmia storm in the era of implantable cardioverter-defibrillator. <i>Postgraduate Medical Journal</i> , 2015, 91, 519-526.	1.8	11
8	Gender differences in the use of primary prevention ICDs in New Zealand patients with heart failure. <i>Heart Asia</i> , 2018, 10, e010985.	1.1	8
9	Long-term outcomes of heart failure patients who received primary prevention implantable cardioverter-defibrillator: An observational study. <i>Journal of Arrhythmia</i> , 2018, 34, 46-54.	1.2	8
10	Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS-QI 33). <i>Journal of Arrhythmia</i> , 2020, 36, 153-163.	1.2	6
11	LV epicardial lead placement at time of cardiac surgery: useful for some-but not all. <i>New Zealand Medical Journal</i> , 2018, 131, 45-49.	0.5	5
12	Outcomes of patients with heart failure after primary prevention ICD unit generator replacement. <i>Heart Asia</i> , 2019, 11, e011162.	1.1	3
13	Utilization of cardiac resynchronization therapy in patients with heart failure in the Northern Region of New Zealand. <i>Journal of Arrhythmia</i> , 2019, 35, 52-60.	1.2	3
14	Ten-year trends in cardiac implantable electronic devices in New Zealand: a national data linkage study (<sc>ANZACS-QI</sc> 51). <i>Internal Medicine Journal</i> , 2022, 52, 614-622.	0.8	3
15	Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?. <i>Heart Failure Reviews</i> , 2017, 22, 305-316.	3.9	2
16	Impact of cardiac resynchronisation therapy on burden of hospitalisations and survival: a retrospective observational study in the Northern Region of New Zealand. <i>BMJ Open</i> , 2019, 9, e025634.	1.9	2
17	Regional variation in cardiac implantable electronic device implants trends in New Zealand over the past decade (<sc>ANZACS-QI</sc> 54). <i>Internal Medicine Journal</i> , 2022, 52, 1035-1047.	0.8	2
18	Adherence to the current guidelines for bradycardic pacing in the octogenarian and nonagenarian populations. <i>New Zealand Medical Journal</i> , 2016, 129, 33-40.	0.5	0

#	ARTICLE	IF	CITATIONS
19	S pneumoniae purulent pericarditis in the setting of community-acquired pneumonia. New Zealand Medical Journal, 2017, 130, 80-85.	0.5	0